Because the medications produced by Set Pharma have shown positive effects in the treatment of a certain type of blood cancer.

According to Cett Pharmaceuticals, new clinical data shows that their monoclonal antibody drug INCA033989 can rapidly and significantly reduce the spleen volume of patients with a specific gene mutation associated with bone marrow fibrosis, alleviate related symptoms, and improve anemia. Preliminary study results come from using the drug as a monotherapy and in combination with ruxolitinib, targeting patients with CALR mutations in bone marrow fibrosis. The drug has shown good safety and no dose-limiting toxic reactions have been reported. Cett Pharmaceuticals plans to initiate a registration project for the treatment of bone marrow fibrosis in 2026.